Other substances

Enalapril

An ACE inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

2
 Supporting references
0
 Contradictory references
4
 AI-suggested references
0
 Clinical trials

General information

Enalapril on PubChem

Marketed as

ACETEC; ACETENSIL; ALAPREN; AMOTAC; AMPRACE; DILVAS; DIOTENSIL; DREPATIL; ENACE; ENAHEXAL; ENAL; ENALAPOTEN; ENALAPRIL; ENPRIL; FELIBERAL; GADOPRIL; GLIOTEN; KINFIL; VASOTEC

 

Structure image - Enalapril

CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O

Supporting references

Link Tested on Impact factor Notes Publication date
Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay
Preprint Screening 		in vitro

(maleate salt) inhibitor of the ACE2-RBD interaction

 Jun/16/2020
In-silico drug repurposing study: Amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex
Spike protein ACE2 Small molecule In silico 		in silico

Predicted to destabilize the SARS-CoV-2 Spike-host's ACE2 receptor interface.

 Dec/28/2020

AI-suggested references

Link Publication date
Treatment of Focal and Segmental Glomerulosclerosis Secondary to High Altitude Polycythemia with Acetazolamide.
Apr/08/2022
Molecular modeling of the interaction of ligands with ACE2-SARS-CoV-2 spike protein complex
Oct/07/2021
Carnosine to Combat Novel Coronavirus (nCoV): Molecular Docking and Modeling to Cocrystallized Host Angiotensin-Converting Enzyme 2 (ACE2) and Viral Spike Protein
Mar/05/2021
Gene signatures and potential therapeutic targets of Middle East respiratory syndrome coronavirus (MERS-CoV)-infected human lung adenocarcinoma epithelial cells.
Mar/26/2021
Export (.csv)